1-4 of 4
Marie-Anne Couturier, MD
Close
Sort by
Journal Articles

Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutic: Results from a 29 Patient-Cohort of a Compassionate Use/Expanded Access Treatment Program

Florent Malard, MDPhD, Michael Loschi, MD PhD, Faezeh Legrand, MD, Raynier Devillier, Sarah Guenounou, MD, Cecile Borel, MD, Deborah Desmier, MD, Jérôme Cornillon, MD, Amandine Le Bourgeois, MD, Jean-Baptiste Mear, MD, Delphine Martineau, MD, Hélène Labussière, MD, Marie-Anne Couturier, MD, Claude-Eric Bulabois, MD, Emilie Plantamura, PhD PharmD, Mohamad Mohty, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15.
https://doi.org/10.1182/blood-2020-136604
Published: 2020
Journal Articles

Values of Hematopoietic Cell Transplantation-Specific Comorbidity Index, Comorbidity/Age Index and Augmented Comorbidity/Age Index in Recipients of Haploidentical Stem Cell Transplantation Using Ptcy As Gvhd Prophylaxis: A Retrospective Study of 223 Cases

Maxime Jullien, MD, Sylvie François, MD, Ana Berceanu, MD, Marie-Anne Couturier, MD, Thierry Guillaume, MD PhD, Pierre Peterlin, MD, Alice Garnier, MD, Amandine Le Bourgeois, MD, Marion Klemencie, MD, Aline Schmidt, MDPhD, Mathilde Hunault, MDPhD, Etienne Daguindau, MD, Eric Deconinck, MDPhD, Gaelle Guillerm, MD, Aurelien Giltat, MD, Corentin Orvain, MD PhD, Sylvain Thepot, MD, Steven Le Gouill, MD PhD, Marie C Bene, PharmSci, PhD, Patrice Chevallier, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
https://doi.org/10.1182/blood-2020-138656
Published: 2020
Journal Articles

Blinatumomab + Ponatinib for Relapsed Ph1-Positive Acute Lymphoblastic Leukemia: The French Experience

Marie-Anne Couturier, MD, Xavier Thomas, MD, Francoise Huguet, MD, Céline Berthon, MD PhD, Célestine Simand, MD, Yosr Hicheri, Mathilde Hunault, MD PhD, Patrice Chevallier, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4014.
https://doi.org/10.1182/blood-2018-99-111546
Published: 2018
Journal Articles

Safety and Long-Term Efficacy of Maintenance Therapy with Alternating Azacytidine (AZA) and Lenalidomide (Len) Cycles in Elderly (≥ 60) Fit Patients (Pts) with Poor Prognosis AML in First Complete Remission (CR) After LIA Induction. A Phase II Multicentric GOELAMS Trial

Mathilde Hunault, MD PhD, Nathalie Maillard, MD, Aline Tanguy-Schmidt, MD, Chantal Himberlin, MD, Bachra Choufi, MD, Caroline Bonmati, MD, Marie Anne Couturier, MD, Eric Deconinck, MD PhD, Jean Pierre Marolleau, MD PhD, Frédérique Orsini-Piocelle, MD, Jacques Delaunay, MD, Emmanuelle Tavernier, MD, Christian Récher, MDPhD, Severine Lissandre, MD, Mario Ojeda-Uribe, MD, Laurence Sanhes, MD, Laurent Sutton, MD, Anne Banos, MD, Bruno Lioure, MD, Marc Bernard, MD, Didier Bouscary, MDPhD, Alain Saad, MD, Valérie Rouille, Philippe Guardiola, MD, Isabelle Luquet, MD, Marie C Bene, PharmSciD, PhD, Francois Dreyfus, MD, Jean-Yves Cahn, MD, Arnaud Pigneux, Norbert Ifrah, MD
Journal: Blood
Blood (2015) 126 (23): 3787.
https://doi.org/10.1182/blood.V126.23.3787.3787
Published: 2015